[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunization-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunization-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,79,111,140,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100512024","phase-2-high-vsstandard-dose-influenza-vaccine-in-pediatric-solid-organ-transplant-sot-recipients-100512024",false,"NCT05947071","High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","Comparison of High vs Standard Dose Influenza Vaccines in Pediatric Solid Organ Transplant Recipients","PSOT","Inclusion Criteria:\n\n1. Male or female, 3-17 years of age at time of enrollment\n2. Pediatric kidney, heart, and\u002For liver transplant recipient ≥1 month and \\\u003C24 months post-transplant at the time of study immunization\n\n   * Note: Inclusion of recipients of multiple organs is permitted but is limited to recipients of any combination of organs including kidney, heart and\u002For liver\n   * Note: Participants undergoing re-transplantation are permitted\n3. Anticipated to be available for duration of the study\n4. Available by telephone, email, or text message\n\nExclusion Criteria:\n\n1. Inability (i.e. not able to understand and provide consent) or unwillingness of a participant\u002Fparent\u002Flegal guardian to give written informed consent or comply with study protocol\n2. History of severe hypersensitivity to influenza vaccination or anaphylaxis to eggs\u002Fegg protein\n3. History of severe latex hypersensitivity\n4. History of Guillain-Barre syndrome\n5. History of lung or intestine transplant\n6. HIV positive patients (testing within 24 months of enrollment)\n7. Receipt of current season's influenza vaccine post-transplant prior to enrollment in the study\n8. Currently pregnant or lactating (females of childbearing age may be enrolled based on self-report, urine pregnancy test must be performed prior to each influenza vaccine)\n9. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.","ALL","3 Years","17 Years",{"count":21,"type":22},312,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT recipients and noted that HD-IIV was safe and more immunogenic; however, the median post-transplant period was 38 months. A phase I pediatric study comparing a single dose of HD-IIV vs. SD-IIV was safe with higher immunogenicity, but the study was limited by small sample size and median post-transplant vaccine administration was 26 months. In another phase II trial of adult SOT recipients, two doses of SD-IIV one month apart compared to one-dose of SD-IIV revealed modestly increased immunogenicity when given at a median of 18 months post-transplant. Therefore, these studies lack both evaluation in the early post-transplant period and substantive pediatric populations. Additionally, the administration of two-doses of HD-IIV in the same influenza season has not been evaluated in pediatric SOT recipients. Thus, the optimal immunization strategy for pediatric SOT recipients less than 24 months post-transplant is unknown. In addition, immunologic predictors and correlates of influenza vaccine immunogenicity in pediatric SOT recipients have not been well-defined.\n\nThe central hypothesis of our proposal is that pediatric SOT recipients 1-23 months post-transplant who receive two doses of HD-quadrivalent inactivated influenza vaccine (QIV) will have similar safety but higher Hemagglutination Inhibition (HAI) geometric mean titers (GMTs) to influenza antigens compared to pediatric SOT recipients receiving two doses of SD-QIV.",[28,29,30],"Immunization; Infection","Transplantation Infection","Influenza",[30,32,33,34,35,36,37,38,39],"Vaccination","Immunization","High Dose","Fluzone","Standard Dose","Influenza, Human","Communicable Diseases","Pediatric transplantation","RECRUITING","2026-04-16",{"date":43,"type":44},"2026-04-21","ACTUAL",{"date":46,"type":44},"2024-09-26",{"date":48,"type":22},"2027-09-01",{"name":50,"class":51},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",8,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100455804","phase-2-high-vs-standard-dose-influenza-vaccine-in-lung-allograft-recipients-100455804","NCT05215327","High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients","Inclusion Criteria:\n\n1. Lung allograft recipients\n2. Age ≥16 years at time of enrollment\n3. ≥1 month (30 days) and \\\u003C36 months post-lung transplant\n4. Anticipated to be available for duration of the study\n5. Can be reached by telephone, email, or text message\n\nExclusion Criteria:\n\n1. Recipient of multi-organ, extra-pulmonary, and\u002For hematopoietic stem cell transplant\n2. Recipient of a re-do lung transplant\n3. History of severe hypersensitivity to previous influenza vaccination or anaphylaxis to eggs\u002Fegg protein\n4. History of Guillain-Barre syndrome\n5. HIV positive patients, by history or documentation from previous test\n6. History of known severe latex hypersensitivity\n7. History of receiving the current season's influenza vaccine post-transplant prior to enrollment in the study\n8. Pregnant female\n9. Proven influenza disease after September 1st and before first study vaccine (patient can still receive the second influenza vaccination despite proven influenza disease once enrolled)\n10. CMVIG\u002FIVIG\u002FSCIG receipt within 28 days of each vaccine\n11. Receipt of rituximab or other B-cell depleting antibody (including proteasome inhibitors) therapy within 3-months of 1st study vaccine (Day 0).\n12. Receipt of augmented T-cell depleting therapy within 3-months of 1st study vaccine (Day 0)\n13. Investigator concern about study participation","16 Years",{"count":62,"type":22},270,[25],"Lung allograft recipients have a higher burden of influenza disease and greater associated morbidity and mortality compared with healthy controls. Induction and early maintenance immunosuppression is thought to impair immunogenicity to standard dose inactivated influenza vaccine. This early post-transplant period is when immunity is most desirable, since influenza disease during this time frame is associated with adverse consequences. Thus, strategies to reduce severe influenza disease in this highly susceptible population are critical. No trials in lung transplant recipients have evaluated two doses of HD-IIV within the same influenza season as a strategy to improve immunogenicity and durability of influenza prevention. Furthermore, no influenza vaccine trials have focused on enrollment of subjects at early post-transplant timepoints. Very few studies have been performed in solely lung allograft recipients. Immunosuppression intensity is highest in lung patients, thereby limiting comparisons to recipients of heart, liver, and kidney transplants. Therefore, studies to assess both HD-IIV and two-dose strategies in the same influenza season in post-lung transplant recipients are greatly needed.\n\nThe central hypothesis of our proposal is that lung allograft recipients who are 1-35 months post-transplant and receiving two doses of HD-quadrivalent inactivated influenza vaccine (QIV) will have higher HAI geometric mean titers (GMT) to influenza antigens compared to those receiving two doses of SD-QIV. To test this hypothesis and address the above critical knowledge gaps, we propose to conduct a phase II, multi-center, randomized, double-blind, controlled immunogenicity and safety trial comparing the administration of two doses of HD-QIV to two doses of SD-QIV in lung allograft recipients 1-35 months post-transplant. The results of this clinical trial will address significant knowledge gaps regarding influenza vaccine strategies (e.g., one vs. two doses and HD-QIV vs. SD-QIV) and immune responses in lung transplant recipients and will guide vaccine recommendations during the post-transplant period.",[28,29,30],[30,32,33,67,34,35,36,37,38],"Lung Transplantation","2025-12-02",{"date":70,"type":44},"2025-12-08",{"date":72,"type":44},"2022-11-08",{"date":74,"type":22},"2027-12-31",{"name":76,"class":77},"Vanderbilt University Medical Center","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":78},"100602790","covid-19-health-adjustments-in-nutrition-general-wellness-and-exercise-100602790","NCT07128095","COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise","CHANGE","Inclusion Criteria:\n\nMale and female participants. Are between the ages of 18-75. Have a resting blood pressure no higher than 150\u002F90 (stage 2 hypertension). Have a BMI below 35 kg\u002Fm2 (otherwise healthy). Free from metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, and cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n\nDo not have any precluding medical issues that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners).\n\nExclusion Criteria:\n\nYounger than 18 or older than 30. Have a resting blood pressure \\> 150\u002F90. Have a BMI \\> 35 Kg\u002Fm2 or \\\u003C 18 Kg\u002Fm2. History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, and cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n\nMedical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis).\n\nMedical issues that prevent giving blood (e.g., blood thinners). Currently pregnant.",true,"18 Years","75 Years",{"count":90,"type":22},100,"OBSERVATIONAL","The purpose of this study is to find out whether the COVID pandemic has affected participants' current physical activity, fitness, blood pressure, sleep, and mental stress to better understand its long-term health effects. To complete this study, participants will visit the Neurovascular Physiology Laboratory (NVPL) at the Indiana University School of Public Health Bloomington two times, requiring a total commitment of about 6 hours.\n\nVisit 1 involves completing screening questionnaires, a consent document, and additional questionnaires about participant health behaviors (e.g., sleep and physical activity) and general mental and physical health. After the visit, participants will also start tracking their sleep and physical activity using wearable devices for 14 days, diet for at least 3 days, and blood pressure and urine for 24 hours.\n\nVisit 2 is a second data collection visit, where participants will return the wearable devices. The investigators will measure participants' body composition, take measures of their cardiovascular health, and participants will complete a fitness test on a stationary cycle (exercise bike). The investigators will collect a 24 hour urine sample and take a blood sample to measure participants' blood glucose, electrolytes, hydration biomarkers, and markers of inflammation, as well as to study immune cells. The investigators will take participants' blood pressure at rest and during a hand-in-cold water test, which helps assess how participants' nervous system responds to stress. A full-body scan will measure participant body composition including bone density, muscle mass, and body fat percentage. Finally, participants will complete a cycling test that gradually increases in intensity to measure cardiovascular fitness.\n\nRisks involve potential pain or bruising from blood draws, discomfort from blood pressure cuffs, stress from vigorous cycling, and psychological stress from questionnaires. There's also a slight risk of severe cardiovascular events occurring during exercise and loss of data confidentiality. Finally, the cold water test may result in a rare but noted situation where the body's nervous system overreacts to the cold stimulus, leading to a drop in blood pressure and heart rate. Participants will be monitored by trained staff during all procedures to ensure safety.",[94,95,28,96,97,98,99],"COVID-19","Sleep","Physical Inactivity","Blood Pressure","Diet Habit","Mental Health Wellness 1",[94,95,28,96,97,98,101],"Mental Wellness","2025-10-28",{"date":104,"type":44},"2025-10-30",{"date":106,"type":44},"2025-08-22",{"date":108,"type":22},"2026-08-31",{"name":110,"class":77},"Indiana University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":86,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":78},"100505294","phase-1-immunogenicity-of-yellow-fever-vaccine-17d-in-adults-with-prior-17d-vaccination-100505294","NCT05859490","Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination","A Phase I\u002FII Study Of The Immunogenicity Of The Yellow Fever Vaccine 17D (YFVax®) In Adults With Prior 17D Vaccination","Inclusion Criteria:\n\n1. Aged ≥20 to \\\u003C50 years.\n2. Male or female.\n3. In good health at the time of screening as determined by medical history, physical examination, and clinical judgement of the investigator.\n4. Documented history of Yellow fever vaccination 8 or more years prior. Documentation must be on a primary (not copied) vaccination card or a fully completed electronic medical record entry including date of administration and lot number administered.\n5. Subjects who can comply with all trial procedures and are available for the duration of follow-up.\n\nExclusion Criteria:\n\n1. A clinically active infection or self-reported body temperature ≥38°C (100.4°F) within 3 days of scheduled date of vaccination (consider whether the finding is an exclusion criterion or criterion for delay of vaccination see Section 8.3).\n2. A known hypersensitivity or allergy to any of the trial vaccine components including eggs.\n3. Behavioral\u002Fcognitive impairment that, in the investigator's opinion, may interfere with the subject's ability to participate safely in the trial.\n4. Any history of neurologic disorder, seizure disorder or neuro-inflammatory disease.\n5. Any illness, or history of any illness that, in the investigator's opinion, could interfere with the trial or pose an additional risk to the subject during the trial period.\n6. Known or suspected impairment\u002Falteration of immune function, including:\n\n   1. Chronic use of oral steroids within 60 days prior to enrollment. Inhaled steroids are allowed.\n   2. Receipt of parenteral steroids within 60 days prior to screening visit.\n   3. Receipt of immunoglobulins and\u002For any blood products within the 3 months prior to enrollment or planned receipt during the trial.\n   4. Receipt of immunostimulants within 60 days prior to screening visit\n   5. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months of enrollment.\n   6. Known Human Immunodeficiency Virus (HIV) infection or HIV-related disease.\n   7. Hepatitis C virus infection.\n   8. Genetic immunodeficiency.\n7. History of splenic or thymic dysfunction.\n8. Any serious chronic or progressive disease as assessed by the investigator (eg, neoplasm, hematologic malignancies, insulin dependent diabetes; cardiac, renal, or hepatic disease).\n9. Body Mass Index (BMI) greater than or equal to 35 kg\u002Fm2.\n10. Concurrent participation in any clinical trial with another investigational product 30 days prior to or during the conduct of this trial.\n11. Vaccination within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment or plans to receive any vaccine within 28 days of trial vaccine administration (consider whether applicable as an exclusion criterion or criterion for delay of trial vaccine administration).\n12. Use of antipyretics and\u002For analgesic medications within 24 hours prior to vaccination. Trial entry should be delayed to allow for a full 24-hours to have passed since last use of antipyretics and\u002For analgesic medications (consider whether applicable as an exclusion criterion or criterion for delay of trial vaccine administration).\n13. Subjects with history of substance or alcohol abuse within the past 2 years.\n14. Subjects who are pregnant or breastfeeding.\n15. Subjects of childbearing potential who are sexually active with men and have not used \"acceptable contraceptive methods\" for at least 2 months prior to enrollment.\n\n    1. Of \"childbearing potential\" is defined as beyond onset of menarche and not: menopausal for 2 or more years, post bilateral tubal ligation at 1 year prior, post bilateral oophorectomy for at least 1 year or post hysterectomy.\n    2. \"Acceptable birth control methods\" include:\n\n    \u003C!-- -->\n\n    1. Hormonal contraceptives (such as oral, injection, transdermal patch, implant, cervical ring).\n    2. Barrier method (condom with spermicide or diaphragm with spermicide) every time during intercourse.\n    3. Intrauterine device.\n    4. Monogamous relationship with vasectomized partner (partner must have been vasectomized for at least 6 months prior to the subject's enrollment.\n16. Subjects of childbearing potential who are sexually active with men and refuse acceptable contraceptive method up to 28 days after the vaccination.\n17. Any positive or indeterminate pregnancy test.\n18. Planned vaccination (during the trial conduct) against any other vaccine preventable disease.\n19. Planned travel (during the trial) to any YFV endemic area.\n20. Screening serology consistent with prior history of dengue, zika, West Nile or Japanese encephalitis virus infection.\n\nIt may occur that a prospective subject meets all entry criteria except one that relates to short term clinical condition (e.g., fever, recent use of excluded medications). Under these circumstances, eligibility for delayed trial enrollment may be considered after inclusion\u002Fexclusion criteria have been rechecked, and if the subject is confirmed to be eligible.","20 Years","49 Years",{"count":121,"type":22},35,[123,25],"PHASE1","The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are:\n\n* how does prior vaccination affect antibody responses to re-vaccination?\n* how does prior vaccination affect the immune cell response to re-vaccination?\n\nParticipants will:\n\n* have been previously vaccinated with 17D.\n* be re-vaccinated with 17D.\n* provide medical and travel histories.\n* provide a blood sample prior to vaccination\n* provide a blood sample approximately every other day for 14 days after vaccination.\n* provide a blood sample approximately 28 days after vaccination.\n* complete a daily diary of symptoms following vaccination for 14 days.\n* report any additional symptoms after 14 days.",[126,28],"Yellow Fever",[128,129,130],"17D","vaccination","immunity","2025-07-28",{"date":133,"type":44},"2025-07-31",{"date":135,"type":44},"2023-08-01",{"date":137,"type":22},"2025-12-31",{"name":139,"class":77},"Oregon Health and Science University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":78},"100567365","impact-on-quality-of-life-and-burden-of-disease-in-adults-with-herpes-zoster-100567365","NCT06667245","Impact on Quality of Life and Burden of Disease in Adults With Herpes Zoster","1 Prospective cohort study Inclusion criteria Patients \\> 18 years of age who are to be immunized against HZ\n\nExclusion criteria:\n\n* Pregnant women\n* Patients with altered level of consciousness (dementia and others) who do not complete the questionnaires\n* Patients who do not wish to participate in the study 5.2 Retrospective cohort study Inclusion criteria Adults \\>18 years of age with a diagnosis of HZ in the CMBD from 2012 to 2023 at the Jiménez Díaz Foundation hospital. Since the international classification of diseases changed from ICD 9 to ICD 10 in 2106, the codes to be used for the inclusion of patients in the study are described below.\n\nICD 9 053 Herpes zoster\n\nIncludes:\n\n* Herpes zoster\n* Zone 053.0 With meningitis 053.1 With other central nervous system complications\n* 053.10 With unspecified nervous system complications\n* 053.11 Geniculate herpes zoster or Herpetic geniculate ganglionitis\n* 053.12 Postherpetic trigeminal neuralgia\n* 053.13 Postherpetic polyneuropathy\n* 053.14 Herpes zoster myelitis\n* 053.19 Other 053.2 With ophthalmic complications\n* 053.20 Herpes zoster dermatitis of eyelid or Herpes zoster ophthalmicus\n* 053.21 Herpes zoster keratoconjunctivitis\n* 053.22 Herpes zoster iridocyclitis zoster\n* 053.29 Other 053.7 With other specific complications\n* 053.71 Otitis externa due to herpes zoster\n* 053.79 Other 053.8 With unspecified complications 053.9 Herpes zoster without complication Herpes zoster NOS ICD 10 B02 Herpes zoster\n\nIncludes:\n\n* herpes\n* zona B02.0 Encephalitis due to herpes zoster Meningoencephalitis due to zoster B02.1 Meningitis due to herpes zoster B02.2 Herpes zoster with other nervous system involvement\n* B02.21 Postherpetic geniculate ganglionitis\n* B02.22 Postherpetic trigeminal neuralgia\n* B02.23 Postherpetic polyneuropathy\n* B.02.24 Myelitis Postherpetic myelitis\n* B02.29 Other postherpetic nervous system involvement\n* B02.3 Ocular herpes zoster\n* B02.30 Ocular herpes zoster, unspecified\n* B02.31 Herpes zoster conjunctivitis\n* B02.32 Herpes zoster iridocyclitis\n* B02.33 Herpes zoster keratitis\n* B02.34 Herpes zoster scleritis\n* B02.39 Other herpes zoster eye disease\n* B02.7 Disseminated herpes zoster\n* B02.8 Herpes zoster with other complications\n* B02.9 Uncomplicated herpes zoster\n* B02.39 Herpes zoster otitis externa NEOM\n\nExclusion criteria:\n\nPatients who are vaccinated against HZV",{"count":147,"type":22},357,"Title: Impact on quality of life and disease burden in adults with herpes zoster\n\nProspective cohort study for the primary objective and the secondary objectives (1 and 2) and retrospective cohort study for the secondary objective 3.\n\nDisease or disorder under study: Patients with a herpes zoster (HZ) diagnosis.",[150,151,28],"Herpes Zoster","Quality of Life","NOT_YET_RECRUITING","2024-10-30",{"date":155,"type":44},"2024-10-31",{"date":157,"type":22},"2024-11-04",{"date":159,"type":22},"2026-11-04",{"name":161,"class":77},"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":86,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":78},"100498733","evaluation-of-covid-19-immune-barrier-and-reinfection-risk-100498733","NCT05774093","Evaluation of COVID-19 Immune Barrier and Reinfection Risk","COVID","Inclusion Criteria:\n\n1. No age limit, no gender limit;\n2. Medical staff, administrative and logistics staff who work in the Third Affiliated Hospital of Sun Yat-Sen University or other participants who can cooperate with the follow-up for 48 weeks;\n3. The participants need to be sure whether they have ever been infected with COVID-19, and need to be clearly remember the time when they first infected with COVID-19.\n\nExclusion Criteria:\n\n1. Have the following serious respiratory diseases: such as asthma, bronchiectasis, chronic obstructive pulmonary disease, pulmonary interstitial disease, tuberculosis and other respiratory diseases that may interfere with symptom observation;\n2. Those with other serious diseases or disease history that affect immune function, including but not limited to uncontrolled and unresectable malignant tumors,hematological diseases, cachexia, active bleeding, severe malnutrition, mental diseases, autoimmune diseases, HIV, etc.\n3. Those who have long-term assignment plans and cannot return to the hospital regularly for follow-up.",{"count":170,"type":22},300,"The goal of this observational study is to evaluate the protective effect of immune barrier on secondary infection after COVID-19 (coronavirus disease 2019) vaccination or COVID-19 virus Omicron B A. 5.2 strain infection by dynamically monitoring the COVID-19 antibody titer, cellular immune function and the occurrence of secondary infection of healthy participants, mainly medical staff in our hospital, to understand the cross protective effect of COVID-19 antibody on different variants of Omicron, and explore the best time to use COVID-19 vaccine to strengthen immunity after Omicron mutant infection.",[173,28],"COVID-19 Infection","2023-03-15",{"date":176,"type":44},"2023-03-17",{"date":178,"type":44},"2023-03-06",{"date":180,"type":22},"2027-07-31",{"name":182,"class":77},"Sun Yat-sen University"]